Is Concord Medical Services Holdings Limited (NYSE:CCM) a buy in 2026?
No. Concord Medical Services Holdings Limited is one to avoid for now, per the Compass.
A $19M micro-cap Chinese cancer hospital operator burning $313M of free cash flow. The math doesn't work at any price.
Where CCM is headed
Concord Medical operates proton therapy centers and radiotherapy networks across China, a business that sounds like exactly the kind of structural growth story you want exposure to. China's cancer incidence is climbing, proton therapy is one of the most sophisticated treatment modalities available, and the country's middle class increasingly demands Western-grade oncology care. On paper, this should be a compelling growth vehicle. In practice, the numbers describe a company in structural distress dressed up in a growth-story wrapper.
Read the full Compass Direction on CCM
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $3.10).
See the full CCM analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Concord Medical Services Holdings Limited (NYSE:CCM) a buy in 2026?
No. Concord Medical Services Holdings Limited is one to avoid for now, per the Compass. A $19M micro-cap Chinese cancer hospital operator burning $313M of free cash flow. The math doesn't work at any price.
What is CCM's Compass Score?
Concord Medical Services Holdings Limited scores 67/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for CCM?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the CCM page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.